Onconova Therapeutics, Inc. Shares (1) Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • July 18th, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
Leerink Swann LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
LICENSE AGREEMENTLicense Agreement • July 18th, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, Onconova is developing a pharmaceutical product in the United States under the trademark Estybon™ for use in oncology, and owns or controls certain proprietary technology, know-how and information relating to such product;
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • July 18th, 2013 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 19th day of September, 2012 (the “Effective Date”), by and between Onconova Therapeutics, Inc., a company organized under the laws of the State of Delaware with its principal place of business at 375 Pheasant Run, Newtown, PA 18490 (“Onconova”) and Baxter Healthcare SA, a company organized under the laws of the Switzerland with its principal place of business at Thurgauerstrasse 130 8152 Glattpark (Opfikon) Switzerland (“Baxter”). Onconova and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
